Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03427268 · ClinicalTrials.gov registry record · Phase 2
Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment
A Phase 2 study, sponsored by PharmaMar.
- Completed
- Registry status
- Phase 2
- Development phase
- 32
- Enrollment target
NCT03427268 is a Phase 2 study that has completed, run by PharmaMar. The registered enrollment target is 32 participants.
The verdict
NCT03427268, a Phase 2 study, has completed, sponsored by PharmaMar.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 32 participants
- Enrollment target
Study Summary
This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown status) progressing after standard treatments (fluoropyrimidine, irinotecan, and oxaliplatin). Patients in this trial will receive PM060184 at a dose of 9.3 mg/m2 as a 30-minute intravenous (i.v.) infusion on Days 1 and 8 q3wk.
Interventions
- DRUG PM060184
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2018-01-16 |
| Est. Completion | 2019-02-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03427268
The ClinicalTrials.gov registry entry for NCT03427268 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is PharmaMar, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PM060184 is the first listed.
NCT03427268 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03427268 about?
NCT03427268 is a clinical study titled "Clinical Trial of PM60184 in Advanced Colorectal Cancer After Standard Treatment". This trial will evaluate the efficacy of PM060184 in terms of progression-free survival at 12 weeks (PFS3) in advanced or metastatic Colorectal Cancer (CRC) patients with any KRAS mutation status (wild- type; mutated; or unknown status) progressing after standard treatments (fluoropyrimidine, irinot...
What is the current status of trial NCT03427268?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 32 participants. The study started on 2018-01-16. Estimated completion is 2019-02-11.
What interventions are being tested in trial NCT03427268?
The interventions under investigation include: PM060184 (DRUG).
Who is sponsoring clinical trial NCT03427268?
This trial is sponsored by PharmaMar, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.